"Hope for Marta"
The newspaper “El Mundo” devotes an extensive report to Friedreich's Ataxia through the testimony of Marta, a 13-year-old girl, who began to show the first symptoms of this rare disease when she was only five years old.
The report highlights the research performed by IRB Barcelona aimed to develop an injectable frataxin treatment that can reach the brain. Frataxin is the protein that is reduced in those affected by this disease.
Meritxell Teixidó, the researcher behind the project, which also involves Macarena Sánchez and Ernest Giralt, stresses: "I believe that in 10 or 15years there will be a therapy that turns Friedreich's Ataxia into a chronic disease." And she adds, “the dream would be to stop it completely or, at least, to slow down its progress.”
Link to El Mundo
Related content
News
Betevé TV’s “Notícies Vespre” (Evening News) has broadcasted an interview with Jordi Durán, researcher with the Metabolic Engineering and Diabetes Therapy Lab at IRB Barcelona, about research into rare diseases.
This lab carries out research into Lafora disease, a genetic neurodegenerative disorder. “The aim of this work is to explain why neurons degenerate and die. What happens is that glucose, a cellular product accumulates, and this causes the neurons to progressively die, causing neurodegeneration,” says Durán.
Nostrum Biodiscovery, a spin-off from IRB Barcelona and the BSC-CNS, focuses on computational simulation to design new drugs and biotech molecules for the market.
The Senén Vilaró Prize is given each year by the “Consejo Social” of the UB and the Bosch i Gimpera Foundation to the best innovative company.
Kennedy’s disease is an untreatable neuromuscular disorder considered a rare disease
A study led by Xavier Salvatella may pave the way for new lines of treatment for Kennedy’s disease
